IMRIS receives allowance of MR-guided therapy patent

2012-09-05 11:12 ET - News Release

 

Mr. Brad Woods reports

IMRIS ANNOUNCES ALLOWANCE OF US PATENT IN MR GUIDED RADIATION THERAPY AND FIRST PRODUCT CLEARANCE IN THEIR IMAGE GUIDED RADIATION THERAPY BUSINESS

IMRIS Inc. has been allowed the U.S. patent for magnetic-resonance-guided (MR-guided) radiation therapy involving the combination of radiation therapy and a movable magnet system. In addition, the U.S. Food and Drug Administration (FDA) recently cleared the first of several products in its MR-guided radiation therapy business.

The recently cleared MR imaging radiation oncology package is for pelvic, brain and head and neck imaging. The package includes magnetic resonance imaging (MRI) coil sets and a specialized imaging tabletop intended for physicians conducting diagnostic MR imaging for radiation therapy treatment planning and simulation.

"We are on our way to building our image-guided radiation therapy business and producing essential tools for enhancing MR image targeting in cancer treatments to support radiotherapy utilized by half of all U.S. cancer patients each year," said David Graves, chairman and chief executive officer of IMRIS. "This patent is significant. MR is the gold standard in soft-tissue imaging accuracy. Ultimately, we are working to improve treatment targeting so patients in the future may have fewer radiation sessions and experience less damage to healthy tissue adjacent to the target."

The oncology package is the first regulatory submission IMRIS filed with the FDA for products related to image-guided radiation therapy systems.